891783-57-6Relevant academic research and scientific papers
Amide derivative and preparation method thereof and medical application
-
Paragraph 0246; 0247; 0250, (2019/10/01)
The invention relates to an amide derivative and a preparation method thereof and medical application, in particular to a compound in the formula (I) and pharmaceutically acceptable salt thereof or astereisomer, a preparation method of the compound and ap
AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF
-
Paragraph 00437, (2018/03/25)
The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (
Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine
Zhang, Shijun,Zhen, Juan,Reith, Maarten E.A.,Dutta, Aloke K.
, p. 3953 - 3966 (2007/10/03)
In our effort to further understand interaction of novel pyran derivatives with monoamine transporters, we have designed, synthesized, and biologically characterized side-chain-extended derivatives of our earlier developed cis- and trans-(6-benzhydryl-tetrahydro-pyran-3-yl)-benzylamine derivatives. Both 3- and 6-position extensions were explored. All synthesized derivatives were tested for their affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuring their potency in inhibiting the uptake of [3H]DA, [3H]5-HT, and [3H]NE, respectively. Compounds were also tested for their binding affinity at the DAT by their ability to inhibit binding of [3H]WIN 35, 428. The results indicated that extension at the 3-position resulted in loss of activity compared to the original compound I. On the other hand, extension at the 6-position resulted in improvement of activity in the compound cis-12 by 2-fold over the parent compound I indicating favorable interaction. In addition, two glycoside derivatives were designed, synthesized, and biologically characterized. The glycosidic trans-isomer 24 exhibited highest potency for the NET in the current series of compounds.
